[Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
Prostate cancer represents one of the most prevalent malignancies in men. Standard therapy of metastatic prostate cancer consists of androgen deprivation, which is a palliative therapy yielding a clinical response of limited duration. In hormone-refractory prostate cancer (HRPC), response to chemotherapy with regimens available until about ten years ago has been disappointing. Nowadays, due to increasing life expectancy and earlier diagnosis and therapy of prostate cancer, more patients with hormone-refractory disease are still in relatively good overall condition. With the taxanes, much more effective cytostatic substances for chemotherapy of HRPC are available today. Using modern taxane-based chemotherapy, effective palliation of pain can be achieved in 50-70% of patients with HRPC, while retaining an acceptable quality of life. There is also evidence for improved overall survival after taxane-based chemotherapy, although this remains to be proven by ongoing studies. This article presents an overview of current studies investigating the outcome after taxane-based chemotherapy, as well as new therapeutic approaches in combination with docetaxel.
Johannsen
M
M
Klinik und Poliklinik für Urologie, Humboldt-Universität, Berlin, Germany. manfred.johannsen@charite.de
Wilke
K
K
Schnorr
D
D
Loening
S A
SA
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D010146:Pain / Q000150:complications / Q000188:drug therapy*; D010166:Palliative Care / Q000379:methods*; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel